AXIM Biotech to Present at 2017 Marcum Microcap Conference in New York City

NEW YORK, June 14, 2017 -- AXIM^® Biotechnologies, Inc. (AXIM^® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that George Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM, will present at the 2017 Marcum Microcap Conference on June 15 at 9:00 am ET in the Uris Boardroom at the Grand Hyatt Hotel in New York City. Management will also be holding 1-on-1 meetings with investors at the Conference.

Since its launch in 2012, this event has become a nationally recognized forum for publicly traded companies to network with fund managers and high net worth investors who focus on small cap equities.

The conference will feature presentations by CEOs and CFOs in seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity for investors to meet with management of presenting companies on a one-on-one basis. Keynote speakers include political consultant James Carville, host of CNN’s Crossfire, Mary Matalin, and CNBC Senior Contributor Lawrence Kudlow.

AXIM’s presentation will be available on the corporate website.

About AXIM^®
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

About Marcum 
Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation, with offices in major business markets throughout the U.S., as well as Grand Cayman, China and Ireland. Headquartered in New York City, Marcum provides a full spectrum of traditional tax, accounting and assurance services; advisory, valuation and litigation support; and an extensive range of specialty and niche industry practices. The Firm serves both privately held and publicly traded companies, as well as high net worth individuals, private equity funds and hedge funds, with a focus on middle-market companies and closely held family businesses.  Marcum is a member of the Marcum Group, an organization providing a comprehensive array of professional services. For more information, visit www.marcumllp.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM^® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
[email protected]
P. +1888 829-0070
www.cmwmedia.com

Investor Relations Contact
Shiwei Yin, Grayling
[email protected]
P. +1646 284-9474
Lucia Domville, Grayling
[email protected]
P. +1646 284-9416

Corporate Contact Info
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227